Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of PXD101 and Doxorubicin to Treat Soft Tissue Sarcomas

This study has been completed.
Spectrum Pharmaceuticals, Inc
Information provided by (Responsible Party):
TopoTarget A/S Identifier:
First received: April 7, 2009
Last updated: November 29, 2013
Last verified: November 2013

The present PXD101-CLN-14 study is an open-label non-randomized, multicenter, phase I/II trial to assess the efficacy and safety of PXD101 in combination with doxorubicin in patients with soft tissue sarcomas (and in the dose escalation phase all solid tumours) in need of chemotherapy.

Condition Intervention Phase
Soft Tissue Sarcomas
Drug: PXD101 + doxorubicin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

Resource links provided by NLM:

Further study details as provided by TopoTarget A/S:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT)) and efficacy of PXD101 and doxorubicin combination treatment measured by response rate using the RECIST response criteria. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The time to response, duration of response, and survival following PXD101 combination therapy disease control rate (CR+PR+SD) PK of PXD101 and doxorubicin in the combination PD aspects of the treatment [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Enrollment: 47
Study Start Date: December 2006
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BelDox IV Drug: PXD101 + doxorubicin
5-day PXD101 schedule with dose escalation combined with doxorubicin
Other Names:
  • PXD101 (Belinostat)
  • Doxorubicin (Adriamycin)

Detailed Description:

This trial is an open-label, multicentre, dose-escalation Phase I/II study to evaluate safety, efficacy, pharmacodynamics, and pharmacokinetics of the combination of PXD101 with doxorubicin administered q 3 weeks in patients with advanced solid tumours. Once the MTD has been established, up to a total of 20-40 patients with STS may be enrolled at the MTD dose level to examine efficacy and safety in this specific patient population. The trial is stopped if no more than 2 responses are seen among the first 20 of these patients.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria: (abbreviated)

  1. Signed consent
  2. For the dose escalation phase: patients with histological or cytological confirmed solid tumours.
  3. For the MTD expansion phase: patients with an established diagnosis of soft tissue sarcoma in need of first line chemotherapy and with measurable disease
  4. Performance status (ECOG) ≤ 2
  5. Life expectancy of at least 3 months
  6. Age ≥ 18 years
  7. Acceptable liver, renal and bone marrow function as defined
  8. Acceptable coagulation status as defined

Exclusion Criteria:

  1. Treatment with investigational agents within the last 4 weeks
  2. Prior anticancer therapy, within the last 3 weeks of trial
  3. Co-existing active infection or any co-existing medical condition likely to interfere with trial procedures, including significant cardiovascular disease
  4. Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
  5. Concurrent second malignancy
  6. History of hypersensitivity to doxorubicin
  7. A. For dose escalation phase: More than two prior doses of anthracycline, more than three prior lines of chemotherapy given for metastatic disease B. For MTD expansion phase: Prior chemotherapy
  8. Bowel obstruction or impending bowel obstruction
  9. Known HIV positivity
  10. LVEF below normal range (45% by MUGA)
  11. Presence of metastatic disease that, in the opinion of the investigator, would require palliative treatment within 4 weeks of enrolment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00878800

Herlev Hospital, Department of Oncology
Herlev, Denmark, DK-2730
Århus Hospital, Department of Oncology
Århus, Denmark, DK-8000 C
United Kingdom
The Royal MarsdenNHS Trust, Cancer Research
Surrey, United Kingdom, SM2 5PT Surrey
Sponsors and Collaborators
TopoTarget A/S
Spectrum Pharmaceuticals, Inc
Principal Investigator: Ole Steen Nielsen, MD Århus Hospital, Department of Oncology
Principal Investigator: Ian Judson, MD Royal Marsden NHS Foundation Trust
Principal Investigator: Anders K Hansen, MD Herlev Hospital, Deparment of Oncology
  More Information

No publications provided

Responsible Party: TopoTarget A/S Identifier: NCT00878800     History of Changes
Other Study ID Numbers: PXD101-CLN-14
Study First Received: April 7, 2009
Last Updated: November 29, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by TopoTarget A/S:
Phase I/II trial
Soft tissue sarcoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on November 20, 2014